Strengthening the Provision of Accessible and Quality Assured Laboratory Services in Namibia through the Namibia Institute of Pathology for Sustained Epidemic Control of HIV and TB under PEPFAR

The summary for the Strengthening the Provision of Accessible and Quality Assured Laboratory Services in Namibia through the Namibia Institute of Pathology for Sustained Epidemic Control of HIV and TB under PEPFAR grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Centers for Disease Control CGH, which is the U.S. government agency offering this grant.

Strengthening the Provision of Accessible and Quality Assured Laboratory Services in Namibia through the Namibia Institute of Pathology for Sustained Epidemic Control of HIV and TB under PEPFAR: The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $3,500,000 for Year 1, subject to the availability of funds. Over the next five years, diagnostic network optimization (DNO) within the laboratory system will be the primary overarching activity since it pinpoints deficiencies and strengthens the identified gaps remaining to reach sustained epidemic control of HIV and TB in Namibia, as well as responds to outbreak needs as they occur. Broadly, the activities under this NOFO will include: 1) the establishment of a national transport system using the Namibia Institute of Pathology (NIP) system as a base, 2) workflow analyses to assess testing needs based on number of patients on antiretroviral therapy (ART), 3) assessment of instrument utilization, and 4) establishment of a national unique patient identifier. These activities will enable the country to better track patients from one viral load (VL) test to the next to ensure suppression rates are accurate for all patients on ART, enhance and expand infant diagnosis to greater than the current 80% coverage, and ensure that all HIV patients that are dually infected with TB are diagnosed and treated.